Burden of Illness for Metastatic Melanoma in Canada, 2011–2013

Ernst, D. Scott; Petrella, Teresa M.; Joshua, Anthony M.; Hamou, Ali; Thabane, Marroon; Vantyghem, Sophie; Gwadry-Sridhar, Femida

doi:10.3747/co.23.3161

Cited by 17 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6,7,33,34,[37][38][39][40][41][42] Several studies have significantly contributed to the understanding of the epidemiology and risk factors for CMM in Canada. 9,14,16,18,28,[43][44][45][46][47][48][49][50][51][52][53][54] We recently reported an extensive analysis of CMM epidemiology in Canada from 1992 to 2010 and highlighted a steady increase in the incidence and mortality of this malignancy in both sexes within the aforementioned time period. 55 Briefly, the most commonly reported specific subtype of CMM in the Canadian population was superficial spreading melanoma, which comprised 37.4% of all CMM cases.…”

Section: Introductionmentioning

confidence: 99%

Incidence, Mortality, and Spatiotemporal Distribution of Cutaneous Malignant Melanoma Cases Across Canada

Ghazawi

Lagacé

et al. 2019

J Cutan Med Surg

View full text Add to dashboard Cite

Background: We recently reported a steady increase in the incidence and mortality of cutaneous malignant melanoma (CMM) in Canada during 1992-2010. Objectives: The objective of this article is to examine the distribution of Canadian CMM patients at the level of provinces, cities, and forward sortation area (FSA) postal codes. Methods: Using 3 Canadian population-based registries, we conducted an in-depth examination of the incidence and mortality trends for 72 565 Canadian CMM patients over the period 1992-2010. Results: We found that among 20- to 39-year-olds, the incidence of CMM in women (7.17 per 100 000 individuals) was significantly higher than in men (4.60 per 100 000 individuals per year). Women age 80 years and older had an incidence of CMM (58.46 cases per 100 000 women per year) more than 4 times greater than the national average (12.29 cases per 100 000 population per year) and a corresponding high mortality rate (20.18 deaths per 100 000 women per year), when compared with the Canadian melanoma mortality of 2.4 deaths per 100 000 per year. In other age groups men had higher incidence and corresponding melanoma mortality rates. We also studied CMM incidence by province, city, and FSA postal codes and identified several high-incidence communities that were located near the coast/waterfronts. In addition, plotting latitude measures for cities and FSAs vs CMM incidence rate confirmed the inverse relationship between geographical latitude and incidence of melanoma in Canada (slope = –0.22 ± 0.05). Conclusions: This research may help develop sex-, age- and geographic region-specific recommendations to decrease the future burden of CMM in Canada.

show abstract

Section: Introductionmentioning

confidence: 99%

Incidence, Mortality, and Spatiotemporal Distribution of Cutaneous Malignant Melanoma Cases Across Canada

Ghazawi

Lagacé

et al. 2019

J Cutan Med Surg

View full text Add to dashboard Cite

show abstract

“…The data showed that the pathologic T stage continued to be in uencing factors of the prognosis of MM patients in TCGA, with p-values of 0.025. For every MM patient, a PI as a risk score was calculated according to equation (1). The PI was signi cantly associated with OBS in metastasis group.…”

Section: Establishment Of the Immune-related Genes Risk Signaturementioning

confidence: 99%

“…Its incidence has increased faster than that of any other cancer over the past half-century and the annual costs of treatment in the United States alone have risen rapidly. The average 5-year survival rate is approximately 90, 70, 40, and less than 10% for patients with stage I, II, III, and IV malignant melanoma, respectively [1][2][3][4]. One of the standard methods of diagnosing and treating melanoma is represented by surgical resection (melanoma is frequently located in the skin, so excision is still widely applied at present for patients with early-stage melanoma due to its facile accessibility).…”

Section: Introductionmentioning

confidence: 99%

“…Although the majority of primary melanomas are cured with local excision, metastatic melanoma historically carries a grim prognosis with a median survival of 9 months and a long-term survival rate of 10% [1,5]. Except for melanoma in situ, the surgical procedure is generally not enough when it is performed as monotherapy [4], local recurrence, and / or metastases develop in most patients after a variable period of time.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of a Prognostic Signature of Malignant Melanoma Based on Tumor Immune Microenvironment Exploration

Yuan¹,

Bing²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: In contrast to identification of well-defined oncogenic alterations like BRAF mutations for malignant melanoma (MM) patient stratification, effective selection of predictive biomarkers remains a challenge in the era of checkpoint blockade.Methods: The differentially expressed genes (DEGs) related to the TME were identified using The Cancer Genome Atlas (TCGA) dataset by Wilcoxon rank sum test. The prognostic effects of immune-related genes (IRGs) were analyzed using univariate Cox regression. Next, the prognostic model was constructed by step multivariate Cox regression and risk score of each sample was calculated. Then, survival and Receiver Operating Characteristic (ROC) analyses were conducted to validate the model using TCGA and the Gene Expression Omnibus (GEO) datasets, respectively. Finally, the overall immune status, tumor purity of high- and low-risk groups was further analyzed to reveal the potential mechanisms of prognostic effects of the model.Results: Twenty eight IRGs were identified, the univariate cox analysis indicated the hazard ratio ranged from 0.796 to 2.621 (p-value < 0.05). 6 genes (SLPI, S100A7, LYZ, CCL19, CXCR4 and CD79A) were screened out by step multivariate cox regression and a 6-IRGs, which can be used as an independent prognostic factor, was constructed. The MM patients in both training (TCGA) and testing (GEO) datasets can be well stratified as high-risk and low-risk groups with the 6-IRGs signature, and the 3-year and 5-year area under curve (AUC) of ROC curves of GEO set were 0.681 and 0.678 (GSE19234). Conclusions: In sum, we identified and constructed a 6-IRGs , which can be used to predict the prognosis of metastasis in MM patients.

show abstract

“…Most cases of melanoma are diagnosed at an early stage, which has been attributed to increased awareness of the malignancy [ 9 ]. At this stage, surgical excision may be curative [ 10 ]. However, a small proportion of patients have metastatic disease at presentation, and some develop metastases after their initial definitive treatment [ 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Understanding Real-World Treatment Patterns and Clinical Outcomes among Metastatic Melanoma Patients in Alberta, Canada

et al. 2023

View full text Add to dashboard Cite

Immunotherapy and targeted therapies have been shown to considerably improve long-term survival outcomes in metastatic melanoma patients. Real-world evidence on the uptake of novel therapies and outcomes for this patient population in Canada are limited. We conducted a population-based retrospective cohort study of all metastatic melanoma patients diagnosed in Alberta, Canada (2015–2018) using electronic medical records and administrative data. Information on BRAF testing for patients diagnosed in 2017 or 2018 was obtained through chart abstraction. In total, 434 metastatic melanoma patients were included, of which 110 (25.3%) were de novo metastatic cases. The median age at diagnosis was 66 years (IQR: 57–76) and 70.0% were men. BRAF testing was completed for the majority of patients (88.7%). Among all patients, 60.4%, 19.1%, and 6.0% initiated first-line, second-line, and third-line systemic therapy. The most common therapies were anti-PD-1 and targeted therapies. The two-year survival probability from first-line therapy, second-line therapy, and third-line therapy was 0.50 (95% CI: 0.44–0.57), 0.26 (95% CI: 0.17–0.40), and 0.14 (95% CI: 0.40–0.46), respectively. In the first-line setting, survival was highest for patients that received ipilimumab or ipilimumab plus nivolumab, while targeted therapy had the highest survival in the second-line setting. This study indicates that novel therapies improve survival in the real world but a considerable proportion of patients do not receive treatment with systemic therapy.

show abstract

Burden of Illness for Metastatic Melanoma in Canada, 2011–2013

Abstract: Background Detailed epidemiology for patients with advanced metastatic melanoma in Canada is not well

Cited by 17 publications

References 37 publications

Incidence, Mortality, and Spatiotemporal Distribution of Cutaneous Malignant Melanoma Cases Across Canada

Incidence, Mortality, and Spatiotemporal Distribution of Cutaneous Malignant Melanoma Cases Across Canada

Identification of a Prognostic Signature of Malignant Melanoma Based on Tumor Immune Microenvironment Exploration

Understanding Real-World Treatment Patterns and Clinical Outcomes among Metastatic Melanoma Patients in Alberta, Canada

Contact Info

Product

Resources

About